Molbio Diagnostics Ltd

AI
Molbio Diagnosti Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Molbio Diagnostics Ltd

₹ 1,493 7.11%
13 Nov - close price
molbiodiagnostics.com BSE: 544866 NSE: MOLBIO
About

Molbio Diagnostics is an innovative point-
of-care (POC) diagnostics company that develops affordable, rapid, and accurate diagnostic solutions for infectious and non-communicable diseases. Its flagship product, Truenat, is a portable, battery-powered PCR testing platform that delivers results within
an hour. Designed for use in resource-limited settings, it enables quick and decentralised disease diagnosis at the point of care.

Through its wholly owned subsidiary,
Bigtec Labs, Molbio has strong research
and development capabilities focused on creating diagnostic platforms for point-of-
care (POC) testing. From product development to large-scale deployment, the company aims
to improve access to reliable and affordable healthcare for everyone.[1]

[ add key points ]
Website BSE NSE
  • Market Cap ₹ 17,201 Cr.
  • Current Price ₹ 1,493
  • High / Low ₹ 1,687 / 926
  • Stock P/E 237
  • Book Value ₹ 125
  • Dividend Yield 0.00 %
  • ROCE 18.5 %
  • ROE 15.6 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company's working capital requirements have reduced from 148 days to 116 days

Cons

  • Stock is trading at 12.0 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Equipment & Supplies Medical Equipment & Supplies

Part of BSE IPO Nifty IPO

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2025 Sep 2025 Mar 2026 Jun 2026 Sep 2026
99.71 580.27 560.62 408.38 259.02
115.82 412.83 401.90 307.80 215.07
Operating Profit -16.11 167.44 158.72 100.58 43.95
OPM % -16.16% 28.86% 28.31% 24.63% 16.97%
0.76 1.09 4.79 3.10 5.77
Interest 3.61 6.98 12.08 10.70 8.86
Depreciation 12.32 13.81 19.60 17.08 23.36
Profit before tax -31.28 147.74 131.83 75.90 17.50
Tax % -23.43% 27.68% 27.32% 30.53% 56.00%
-23.94 106.84 95.83 52.75 7.70
EPS in Rs -2.10 9.74 8.06 5.21 1.31
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
837 1,020 1,446
602 760 1,126
Operating Profit 234 260 320
OPM % 28% 26% 22%
-49 -4 9
Interest 14 18 33
Depreciation 41 45 64
Profit before tax 130 194 231
Tax % 36% 29% 29%
84 139 164
EPS in Rs 9.06 12.86 14.77
Dividend Payout % 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 42%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 10%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 16%
Last Year: 16%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 2 2 11 12
Reserves 821 966 1,158 1,429
184 147 450 390
211 346 496 498
Total Liabilities 1,218 1,461 2,115 2,329
289 290 536 520
CWIP 2 27 11 18
Investments 6 46 6 6
921 1,099 1,562 1,785
Total Assets 1,218 1,461 2,115 2,329

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
10 287 50
-45 -123 -54
-32 -26 276
Net Cash Flow -67 138 273
Free Cash Flow -7 232 1
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 23% 141% 38%

Ratios

Consolidated / View Standalone

Mar 2024 Mar 2025 Mar 2026
Debtor Days 186 97 103
Inventory Days 338 384 285
Days Payable 101 203 126
Cash Conversion Cycle 423 278 261
Working Capital Days 200 128 116
ROCE % 21% 18%

Shareholding Pattern

Numbers in percentages

16 Recently
Sep 2026
41.29%
1.59%
19.09%
38.04%
No. of Shareholders 50,395

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

No data available.

DRHP

Concalls